Pfizer: A Deep Dive into Growth Prospects Amidst Patent Cliffs

Pfizer is positioned as a compelling investment opportunity despite facing post-pandemic challenges. The company's strategic acquisition of Metsera, a robust oncology pipeline, and recent FDA approvals are expected to drive future revenue and margin expansion. While acknowledging potential earnings dilution from Metsera, the overall outlook remains strong, supported by cost-cutting initiatives and an attractive dividend yield. A 'Strong Buy' rating is maintained, underscoring confidence in Pfizer's long-term value.